IP Library Granted Patent US 9,440,916
Granted Patent B2
US 9,440,916 · App. 15/078,179 · Granted Sep 13, 2016

3, 4-bis-benzylsulfonylbutyronitrile and its pharmaceutical use

Inventors: Joseph P. St. Laurent (Lakeville, MA); Gerald S. Jones (Norwood, MA); David M. Bresse (Middleboro, MA); Scott A. Goodrich (Stoughton, MA)
Assignee: OLATEC THERAPEUTICS LLC
C07C317/28C07C315/02C07C319/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,440,916
App. No.
15/078,179
Granted
Sep 13, 2016
Kind
B2
Abstract

The present invention is directed to a method of treating an inflammatory skin disease or disorder, such as dermatitis, psoriasis, acne, or rosacea. The method comprises administering to the subject 3, 4-bis-benzylsulfonylbutyronitrile in an amount effective to reduce or eliminate the symptoms of the inflammatory skin disease or disorder. Topical administration and oral administration are preferred route of administration.

Claims (11)

1. A compound of 3, 4-bis-benzylsulfonylbutyronitrile or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

3. The pharmaceutical composition according to claim 1 , wherein the compound has at least 90% (w/w) purity, and the composition is in a topical form of gels, creams, lotions, ointments, solutions, suspensions, sprays, or patches.

4. The pharmaceutical composition according to claim 3 , wherein the pharmaceutically acceptable carrier is an emollient selected from the group consisting of: lauryl lactate, diethylene glycol monoethyl ether, caprylic/capric triglyceride, octisalate, silicone fluid, squalene, and sunflower oil.

5. The pharmaceutical composition according to claim 2 , wherein the pharmaceutically acceptable carrier is a permeation enhancer selected from the group consisting of lactate esters and diethylene glycol monoethyl ether.

6. The pharmaceutical composition according to claim 5 , further comprising acrylates/C10-30 alkyl and tris(2-hydroxyethyl)amine.

7. The pharmaceutical composition according to claim 2 , wherein the compound has at least 90% (w/w) purity, and the composition is in an oral form of tablets, capsules, granules, powders, or syrups.

8. A process for preparing the compound of claim 1 , comprising the steps of:

(a) reacting benzyl mercaptan with 4-bromo-2-butenenitrile in a basic condition to produce 3,4-bis-benzylthiobutyronitrile, and

(b) oxidizing 3,4-bis-benzylthiobutyronitrile with peroxide to produce 3,4-bis-benzylsulfonylbutyronitrile.

9. The process according to claim 8 , further comprising a step of reacting bromine Br 2 with allyl cyanide in a basic condition to prepare 4-bromo-2-butenenitrile.

Assignments (2)
CHANGE OF NAME Recorded Nov 7, 2023
From: OLATEC THERAPEUTICS LLC
To: OLATEC THERAPEUTICS, INC.
Reel/Frame 065489/0809 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2017
From: ST. LAURENT, JOSEPH P.; JONES, GERALD S.; BRESSE, DAVID M.; GOODRICH, SCOTT A.
To: OLATEC THERAPEUTICS LLC
Reel/Frame 041767/0681 →
Continuity (4)
Continuation In Part PCTUS2014057521 · Sep 25, 2014
Provisional Application 61883129 · Sep 26, 2013
Provisional Application 62138815 · Mar 26, 2015
Related Publication 20160200675A1 · Jul 14, 2016